HC Wainwright & Co. Maintains Neutral on Minerva Neurosciences, Raises Price Target to $11
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Douglas Tsao maintains a Neutral rating on Minerva Neurosciences (NASDAQ:NERV) and raises the price target from $8 to $11.
August 04, 2023 | 10:47 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Minerva Neurosciences' price target has been raised from $8 to $11 by HC Wainwright & Co. The rating remains Neutral.
The news of the price target increase for Minerva Neurosciences by HC Wainwright & Co. is directly related to the company. However, the Neutral rating suggests that the analyst does not expect significant price movement in the short term. Therefore, the short term impact on the stock price is likely to be neutral.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100